Literature DB >> 18646041

Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients.

Po-Lin Tseng1, Ming-Hong Tai, Chao-Cheng Huang, Chih-Chi Wang, Jui-Wei Lin, Chao-Hung Hung, Chien-Hung Chen, Jing-Houng Wang, Sheng-Nan Lu, Chuan-Mo Lee, Chi-Sin Changchien, Tsung-Hui Hu.   

Abstract

BACKGROUND AND OBJECTIVES: To elucidate the clinicopathological correlations among vascular endothelial growth factor (VEGF), microvessel density (MVD) and tumor suppressor gene p53 in hepatocellular carcinomas (HCCs), we adopted a new definition of "VEGF overexpression."
METHODS: The expressions of VEGF, MVD, and p53 in 113 HCC specimens were analyzed by immunohistochemistry.
RESULTS: VEGF expression in surrounding liver tended to be stronger (VEGF overexpression, 31%) than, or similar to (57%) that in HCCs (P = 0.001). P53 positivity was noted in 42 cases (37.1%). MVD ranged from 22 to 201 microvessels/field determined for 5 high-power fields. VEGF expression in HCCs was positively correlated with MVD (P = 0.001). VEGF overexpression is positively correlated with young age (P = 0.008), male gender (P = 0.01), hepatitis B viremia (P = 0.013), high alpha-fetoprotein levels (P < 0.001), p53 (+) (P = 0.036), advanced-stage HCC (P = 0.015), and HCC dedifferentiation (P = 0.004). Survival analyses indicated that VEGF overexpression, high MVD, and advanced-stage HCC were independent poor prognostic factors for disease-free and overall survival.
CONCLUSION: This study provides evidence of a positive association between parameters reflective of angiogenesis, and p53 expression in HCCs. VEGF overexpression exhibited a significant correlation with viremia and survival. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18646041     DOI: 10.1002/jso.21109

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  22 in total

1.  Evaluation of microvessel density of hepatocellular carcinoma and comparison with benign lesions of liver: an immunohistochemical study.

Authors:  S Amoueian; A Attaranzadeh; F Pouralborzi; M Tarhini; M Montazer
Journal:  Iran Red Crescent Med J       Date:  2012-02-01       Impact factor: 0.611

Review 2.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

3.  Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo.

Authors:  Lin Liu; Shukui Qin; Yinghui Zheng; Li Han; Minmin Zhang; Nuo Luo; Zhengcao Liu; Ning Gu; Xiaoyi Gu; Xiaojin Yin
Journal:  Cancer Biol Ther       Date:  2017-02-10       Impact factor: 4.742

4.  Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.

Authors:  Valérie Boige; David Malka; Abderrahmane Bourredjem; Clarisse Dromain; Charlotte Baey; Nathalie Jacques; Jean-Pierre Pignon; Nadege Vimond; Nathalie Bouvet-Forteau; Thierry De Baere; Michel Ducreux; Françoise Farace
Journal:  Oncologist       Date:  2012-06-15

5.  Proteomic identification of CIB1 as a potential diagnostic factor in hepatocellular carcinoma.

Authors:  Tong Junrong; Zhou Huancheng; He Feng; Gao Yi; Yang Xiaoqin; Luo Zhengmao; Zhang Hong; Zeng Jianying; Wang Yin; Huang Yuanhang; Zhang Jianlin; Sun Longhua; He Guolin
Journal:  J Biosci       Date:  2011-09       Impact factor: 1.826

Review 6.  Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis.

Authors:  Yoko Matsuda; Masahito Hagio; Toshiyuki Ishiwata
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

7.  Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma.

Authors:  Mei-Fang Zhang; Zhi-Yi Zhang; Jia Fu; Yu-Feng Yang; Jing-Ping Yun
Journal:  J Transl Med       Date:  2009-12-22       Impact factor: 5.531

Review 8.  Molecular therapies in hepatocellular carcinoma: what can we target?

Authors:  Roberto Galuppo; Dinesh Ramaiah; Oscar Moreno Ponte; Roberto Gedaly
Journal:  Dig Dis Sci       Date:  2014-02-27       Impact factor: 3.199

9.  Prognostic significance of vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis.

Authors:  Ping Zhan; Qian Qian; Li-Ke Yu
Journal:  Hepatobiliary Surg Nutr       Date:  2013-06       Impact factor: 7.293

Review 10.  Antiangiogenic therapies for advanced hepatocellular carcinoma.

Authors:  Keeran R Sampat; Bert O'Neil
Journal:  Oncologist       Date:  2013-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.